| Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation E Bulatov, A Ciulli Biochemical Journal 467 (3), 365-386, 2015 | 177 | 2015 |
| The biological basis and clinical symptoms of CAR-T therapy-associated toxicites A Titov, A Petukhov, A Staliarova, D Motorin, E Bulatov, O Shuvalov, ... Cell death & disease 9 (9), 897, 2018 | 96 | 2018 |
| Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment A Titov, A Valiullina, E Zmievskaya, E Zaikova, A Petukhov, R Miftakhova, ... Cancers 12 (1), 125, 2020 | 58 | 2020 |
| Application of CAR-T cell therapy beyond oncology: autoimmune diseases and viral infections E Zmievskaya, A Valiullina, I Ganeeva, A Petukhov, A Rizvanov, E Bulatov Biomedicines 9 (1), 59, 2021 | 44 | 2021 |
| Adoptive immunotherapy beyond CAR T-cells A Titov, E Zmievskaya, I Ganeeva, A Valiullina, A Petukhov, ... Cancers 13 (4), 743, 2021 | 42 | 2021 |
| Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2) E Bulatov, EM Martin, S Chatterjee, A Knebel, S Shimamura, ... Journal of Biological Chemistry 290 (7), 4178-4191, 2015 | 28 | 2015 |
| Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors E Bulatov, R Sayarova, R Mingaleeva, R Miftakhova, M Gomzikova, ... Cell Death Discovery 4 (1), 103, 2018 | 27 | 2018 |
| Binding and purification of plasmid DNA using multi-layered carbon nanotubes II Shakhmaeva, ER Bulatov, OV Bondar, DV Saifullina, M Culha, ... Journal of biotechnology 152 (3), 102-107, 2011 | 27 | 2011 |
| Key Players In The Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy V Chasov, R Mirgayazova, E Zmievskaya, R Khadiullina, A Valiullina, ... Frontiers in Oncology 10, 1460, 2020 | 25 | 2020 |
| Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases E Bulatov, A Valiullina, R Sayarova, A Rizvanov Immunology Letters 202, 44-51, 2018 | 24 | 2018 |
| Small molecule modulators of RING-type E3 ligases: MDM and Cullin families as targets E Bulatov, A Zagidullin, A Valiullina, R Sayarova, A Rizvanov Frontiers in pharmacology 9, 450, 2018 | 24 | 2018 |
| Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option? R Mirgayazova, R Khadiullina, V Chasov, R Mingaleeva, R Miftakhova, ... Genes 11 (6), 704, 2020 | 23 | 2020 |
| Effect of size and protein environment on electrochemical properties of gold nanoparticles on carbon electrodes TI Abdullin, OV Bondar, II Nikitina, ER Bulatov, MV Morozov, ... Bioelectrochemistry 77 (1), 37-42, 2009 | 22 | 2009 |
| Promising new tools for targeting p53 mutant cancers: Humoral and cell-based immunotherapies V Chasov, M Zaripov, R Mirgayazova, R Khadiullina, E Zmievskaya, ... Frontiers in Immunology 12, 707734, 2021 | 20 | 2021 |
| Novel Isatin-based activator of p53 transcriptional functions in tumor cells R Mirgayazova, R Khadiullina, R Mingaleeva, V Chasov, M Gomzikova, ... Molecular Biology Research Communications 8 (3), 119, 2019 | 19 | 2019 |
| Ubiquitin-Proteasome System: Promising Therapeutic Targets in Autoimmune and Neurodegenerative Diseases E Bulatov, S Khaiboullina, H José dos Reis, A Palotás, K Venkataraman, ... Bionanoscience, 2016 | 17 | 2016 |
| Serendipitous SAD solution for DMSO-soaked SOCS2-elonginC-elonginB crystals using covalently incorporated dimethylarsenic: insights into substrate receptor conformational … MS Gadd, E Bulatov, A Ciulli PloS one 10 (6), e0131218, 2015 | 14 | 2015 |
| Knowns and unknowns about CAR-T cell dysfunction A Titov, Y Kaminskiy, I Ganeeva, E Zmievskaya, A Valiullina, ... Cancers 14 (4), 1078, 2022 | 11 | 2022 |
| Discovery of nanomolar-affinity pharmacological chaperones stabilizing the oncogenic p53 mutant Y220C JR Stephenson Clarke, LR Douglas, PJ Duriez, DI Balourdas, AC Joerger, ... ACS Pharmacology & Translational Science 5 (11), 1169-1180, 2022 | 9 | 2022 |
| Design, synthesis and biological evaluation of 2-quinolyl-1, 3-tropolone derivatives as new anti-cancer agents EA Gusakov, IA Topchu, AM Mazitova, IV Dorogan, ER Bulatov, ... RSC advances 11 (8), 4555-4571, 2021 | 9 | 2021 |
Albert RizvanovKazan Federal UniversityAdresă de e-mail confirmată pe kpfu.ru
